Tango Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to advancing targeted cancer therapies. The company's proprietary discovery platform utilizes CRISPR-based screening and the concept of synthetic lethality to identify vulnerabilities in cancer cells, particularly those with tumor suppressor gene deletions. Its clinical pipeline includes the lead candidate vopimetostat, which is being evaluated in registrational trials, alongside other programs targeting specific genetic mutations in various cancers. Tango has also established strategic collaborations with major pharmaceutical companies, such as Gilead Sciences, to expand its research into immune evasion targets. The company is headquartered in Boston, Massachusetts.
